Lexicon Pharmaceuticals

Yahoo Finance • 11 days ago

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5%

LEXICON PHARMACEUTICALS (NASDAQ:LXRX) REPORTS Q2 2025 EARNINGS: REVENUE SURPASSES ESTIMATES, MARKET REACTS POSITIVELY Lexicon Pharmaceuticals Inc (NASDAQ:LXRX [https://www.chartmill.com/stock/quote/LXRX]) reported its second-quarter 2025... Full story

Yahoo Finance • 11 days ago

Lexicon Pharmaceuticals GAAP EPS of $0.01 beats by $0.09, revenue of $28.87M

* Lexicon Pharmaceuticals press release [https://seekingalpha.com/pr/20190800-lexicon-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:LXRX [https://seekingalpha.com/symbol/LXRX]): Q2 GAAP EPS... Full story

Yahoo Finance • 11 days ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to subm... Full story

Yahoo Finance • 25 days ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. M... Full story

Yahoo Finance • 30 days ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatmen... Full story

Yahoo Finance • last month

Lexicon Q1 2025 slides: EPS beat, revenue miss, strategic partnerships advance

Introduction & Market Context Lexicon Pharmaceuticals (NASDAQ:LXRX) presented its first quarter 2025 earnings on May 13, highlighting financial restructuring efforts and strategic partnerships amid ongoing revenue challenges. The company... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock

Investing.com - H.C. Wainwright maintained its buy rating and $4.00 price target on Lexicon Pharmaceuticals (NASDAQ:LXRX) stock following new data presented at the American Diabetes Association conference. With the stock currently tradin... Full story

Yahoo Finance • 3 months ago

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article. Wall Street analysts believe LXRX has a 285% upside po... Full story

Yahoo Finance • 3 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) announced an exclusive license agreement with Novo... Full story

Yahoo Finance • 3 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Confere... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-in... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 i... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call a... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the m... Full story

Yahoo Finance • 6 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results f... Full story

Yahoo Finance • 7 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The ev... Full story

Yahoo Finance • 2 years ago

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

Over the long run, Wall Street has proved to be a surefire wealth creator. But over shorter periods, the performance of the major stock indexes is unpredictable. Since this decade began, the Dow Jones Industrial Average, S&P 500, and Nasda... Full story

Yahoo Finance • 2 years ago

3 of the Fastest-Growing Stocks on the Planet in 2024

Although it's been an adventurous couple of years for investors, 2023 turned out to be a phenomenal year for the bulls. The Dow Jones Industrial Average climbed to a fresh all-time high, while the S&P 500 and Nasdaq Composite respectively... Full story

Yahoo Finance • 2 years ago

7 Magnificent Stocks That Can Double Your Money in 2024

What a difference a year can make on Wall Street. After enduring two bear markets in less than three years, all three major indexes soared in 2023. The iconic Dow Jones Industrial Average climbed to a record high, while the broad-based S&P... Full story

Yahoo Finance • 2 years ago

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Ascending Bar Chart Line Invest Financial Newspaper Stock Market Quote Rally Bull Getty In less than a week, Wall Street will turn the page on what's been a stellar year for optimists. The 30-component Dow Jones Industrial Average climbed... Full story